|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC141 |
Gene summary for CCDC141 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC141 | Gene ID | 285025 |
| Gene name | coiled-coil domain containing 141 | |
| Gene Alias | CAMDI | |
| Cytomap | 2q31.2 | |
| Gene Type | protein-coding | GO ID | GO:0006928 | UniProtAcc | B8ZZB3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 285025 | CCDC141 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 7.31e-03 | 5.54e-01 | -0.1406 |
| 285025 | CCDC141 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.67e-11 | 6.10e-01 | -0.2116 |
| 285025 | CCDC141 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 2.37e-02 | 4.54e-01 | -0.1941 |
| 285025 | CCDC141 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 7.22e-04 | 5.15e-01 | -0.2107 |
| 285025 | CCDC141 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.58e-07 | 4.38e-01 | -0.2119 |
| 285025 | CCDC141 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.39e-03 | 2.15e-01 | -0.0166 |
| 285025 | CCDC141 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 4.32e-03 | 1.56e-01 | -0.013 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00219872 | Lung | IAC | cerebral cortex development | 27/2061 | 114/18723 | 8.78e-05 | 1.77e-03 | 27 |
| GO:00215432 | Lung | IAC | pallium development | 33/2061 | 169/18723 | 7.51e-04 | 9.82e-03 | 33 |
| GO:00309002 | Lung | IAC | forebrain development | 61/2061 | 379/18723 | 1.52e-03 | 1.61e-02 | 61 |
| GO:00516424 | Lung | IAC | centrosome localization | 10/2061 | 32/18723 | 1.68e-03 | 1.76e-02 | 10 |
| GO:00618424 | Lung | IAC | microtubule organizing center localization | 10/2061 | 33/18723 | 2.18e-03 | 2.15e-02 | 10 |
| GO:0021795 | Lung | IAC | cerebral cortex cell migration | 11/2061 | 42/18723 | 4.72e-03 | 3.68e-02 | 11 |
| GO:0022029 | Lung | IAC | telencephalon cell migration | 13/2061 | 56/18723 | 6.78e-03 | 4.73e-02 | 13 |
| GO:003090011 | Lung | AIS | forebrain development | 55/1849 | 379/18723 | 2.37e-03 | 2.48e-02 | 55 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC141 | SNV | Missense_Mutation | novel | c.1604C>T | p.Ser535Leu | p.S535L | protein_coding | tolerated(0.4) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
| CCDC141 | SNV | Missense_Mutation | novel | c.2212N>G | p.Phe738Val | p.F738V | protein_coding | tolerated(0.49) | benign(0.012) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| CCDC141 | SNV | Missense_Mutation | c.2125N>C | p.Val709Leu | p.V709L | protein_coding | tolerated(0.66) | benign(0.007) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | ||
| CCDC141 | SNV | Missense_Mutation | rs550596462 | c.1859N>T | p.Thr620Ile | p.T620I | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-D8-A1XC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| CCDC141 | SNV | Missense_Mutation | c.1517N>T | p.Ser506Leu | p.S506L | protein_coding | deleterious(0.03) | benign(0.044) | TCGA-E2-A1IH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | ||
| CCDC141 | insertion | Nonsense_Mutation | novel | c.966_967insTTAATTCTATCTCCTCCCCCTCAACTGTAACAAATCCACA | p.Ser323LeufsTer10 | p.S323Lfs*10 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| CCDC141 | insertion | Nonsense_Mutation | novel | c.967_968insCAGTGGTAATAATATTTGCTATCTAGACATT | p.Ser323ThrfsTer9 | p.S323Tfs*9 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| CCDC141 | insertion | Frame_Shift_Ins | novel | c.2123_2124insATATAAAG | p.Val709TyrfsTer39 | p.V709Yfs*39 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |||
| CCDC141 | insertion | Nonsense_Mutation | novel | c.2122_2123insACCTTTAAGAAAAATAAAAGGTAAC | p.Ser708TyrfsTer3 | p.S708Yfs*3 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |||
| CCDC141 | insertion | Frame_Shift_Ins | novel | c.1968_1969insATGTGGGTTACTTTTAAACATTTAGA | p.Asp657MetfsTer43 | p.D657Mfs*43 | protein_coding | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |